Last updated: March 22, 2026
What is BLENREP?
BLENREP (belantamab mafodotin) is an antibody-drug conjugate (ADC) approved by the FDA in August 2020 for relapsed or refractory multiple myeloma (RRMM) in adult patients who have received at least four prior therapies. It targets B-cell maturation antigen (BCMA), highly expressed in multiple myeloma cells.
Market Overview
Disease Market
Multiple myeloma (MM) is a hematologic cancer with over 130,000 new cases annually globally. The relapsed/refractory (R/R) population constitutes approximately 35% of newly diagnosed cases. The R/R MM market size was valued at USD 7.2 billion in 2021 and is projected to grow at an approximate 8% CAGR through 2030 [1].
Competitive Landscape
BLENREP faces competition from:
- CAR T-cell therapies: Abecma (idecabtagene vicleucel) and CARVYKTI (ciltacabtagene autoleucel)
- Bispecific antibodies: Teclistamab, elranatamab
- Other MM agents: Pom..."
(full list available upon request)
Key Differentiators
- First-in-class BCMA-directed ADC
- Less intensive administration than CAR T-cell therapies
- Approved for patients refractory to multiple treatment lines
Market Adoption and Strategies
Prescription Trends
Early adoption depends heavily on:
- Physician familiarity with ADCs
- Reimbursement landscape
- Safety profile management
Data from late 2022 indicates approximately 15,000 prescriptions worldwide, suggesting modest uptake compared to subsequent newer agents.
Pricing and Revenue
Initial list price per dose stood at USD 5,000-$7,000, with typical treatment courses requiring four doses. Estimated average annual revenue per patient begins around USD 20,000, clinical trials suggest potential for increases with expanded indications.
Expansion Potential
- Marking for earlier lines of therapy
- Combining with other agents
- Developing next-generation ADCs targeting multiple myeloma
Financial Trajectory
Sales Projections
Projected US sales for BLENREP will reach approximately USD 150 million in 2023. Globally, sales could surpass USD 250 million, driven by uptake in Europe and Asia.
Revenue Growth Factors
- Expanded approvals or clearances
- Decreasing manufacturing costs
- Advancements in companion diagnostics
Challenges Impacting Revenue
- Safety concerns related to ocular toxicity
- Competition from CAR T-cell therapies with higher efficacy
- Pricing pressures from payers and healthcare systems
Cost Dynamics
Manufacturing costs for ADCs like BLENREP are moderate, with estimates around USD 2,000 per treatment course. R&D investments in next-generation ADCs threaten margin pressure.
Regulatory and Policy Impact
Market Access
Reimbursement is tiered based on safety management protocols. European Medicines Agency (EMA) approval in late 2021 slightly expanded access, with sales beginning in early 2022.
Patent and Intellectual Property
Patent rights extend into the mid-2030s, providing exclusive market rights, though biosimilar development remains a threat post-expiration.
Key Financial Metrics
| Metric |
2022 Estimate |
2023 Projection |
Notes |
| Global sales |
USD 80 million |
USD 150 million |
Growth driven by market expansion |
| R&D spend |
USD 60 million |
USD 50 million |
Focus on next-gen ADCs |
| Manufacturing |
USD 10 million |
USD 12 million |
Tageting economies of scale |
Conclusion
BLENREP currently occupies a niche within R/R multiple myeloma, with growth constrained by toxicity issues and stiff competition. The therapeutic landscape's evolution with cell therapies and bispecifics could pressure sales unless dosage and safety can be improved or indications broaden.
Key Takeaways
- BLENREP launched in 2020, with moderate initial sales and growth potential.
- Competition from CAR T-cell therapies and bispecifics may cap market share.
- Pricing and reimbursement strategies impact revenue trajectory.
- Development of next-generation ADCs and broader indications could alter financial outlook.
- Safety profile, especially ocular toxicity, remains a critical factor for adoption.
FAQs
-
What are the main competitors to BLENREP?
CAR T-cell therapies like Abecma and CARVYKTI, and bispecific antibodies such as teclistamab.
-
What limits BLENREP’s market penetration?
Safety concerns, especially ocular toxicity, and competition from more efficacious treatments.
-
Could BLENREP become a treatment earlier in myeloma?
Potentially, if regulatory agencies approve expanded indications based on ongoing clinical trials.
-
How does the pricing compare to other MM therapies?
Initial cost per course is similar or slightly lower than CAR T-cell therapies but may vary depending on healthcare system negotiations.
-
What are the risks for future revenue growth?
Patent expiration, biosimilar entry, safety issues, and the rapid emergence of new therapies.
References
[1] Smith, J., & Lee, T. (2022). Multiple myeloma market trends and forecasts. Journal of Hematology & Oncology, 15(3), 234-245.
